CERVICAL CANCER SCREENING PROGRAMME

Reporting year for qualitative data:	2020
Source of qualitative data:	Directly from Programme

Note: Screening with VIA test starts after sexual debut

Organization of screening
An individual/team/institution responsible to coordinate the programme:	No
Dedicated budget for screening programme:	Yes
Documented cancer screening policy:	Yes
Nature of documentation of the policy:	Notification
Year programme was initiated:	1997
Programme introduction was preceded by a pilot:	Yes, but pilot not evaluated
Screening tests provided free of charge:	Yes
Diagnostic tests provided free of charge:	No
Treatment services provided free of charge:	Yes
Information system and data collection
System that collects data:	Individual & Aggregated
• Identification of eligible population:	Individual
• Screening participation:	Individual & Aggregated
• Screening test results:	Individual & Aggregated
• Further assessment:	Individual & Aggregated
• Final pathology diagnosis:	Individual & Aggregated
• Cancer staging:	No
• Treatment:	Individual & Aggregated
The information system exists at national or sub-national level:	Individual: Sub-national Aggregated: Sub-national
The information system collects data outside the programme (opportunistic screening/private sector):	No
Cancer screening data is linked with population-based cancer registry (PBCR):	No
Screening protocol
A screening protocol or guideline:	Yes
Year of published/updated protocol:	2015
Target age (min-max) and screening interval [months] for each test:	VIA (-49 years / [36 months]) Cytology (50-99 years / [12 months])
Triaging test used:	-
Self-collection HPV recommended:	-
"Screen and treat" included in the protocol:	Yes
Treatment modality for "screen and treat":	Thermal ablation Cryotherapy
Invitations for screening and further assessment
Initiatives to create population awareness by the Health Ministry/Health Authority:	Group education One-on-one education
Invitations to eligible population:	No
Source of the eligible individuals identified:	-
Method of invitation:	-
Screening kit included with the invitation:	-
Screen positive individuals actively contacted for further assessment:	Yes
Individuals with a precancer or cancer diagnosis actively contacted:	Yes
Quality Assurance (QA) of screening activities
Documented standard operating procedure/policy for QA:	No
An individual/team/institution responsible for QA:	No
Accreditation of lab services:	Yes
Accreditation of pathology services:	Yes
Documented performance indicators:	Yes
Reference standards for performance indicators:	No
Evaluation reports published in the last five years:	No
Note: Screening with VIA test starts after sexual debut
Performance indicators
Reporting year for quantitative data:	2018
Source of quantitative data:	Demonstration project
Age range and regional limitation if applicable:	HPV (20-69 years)
Invitation coverage (%):
Participation rate (%):
Examination coverage (%):
Completeness of data related to screening test results (%):	100.0
Completeness of data related to further assessment results (%):
Further assessment (Colposcopy referral) rate (%):	14.8
Further assessment participation rate (%):
Detection rate for CIN2+ (x 1000):
Detection rate for CIN3+ (x 1000):
Detection rate for invasive cancer (x 1000):
Positive Predictive Value of abnormal screening test to detect CIN2+ (x 1000):
Positive Predictive Value for CIN3+ (x 1000):
Positive Predictive Value for invasive cancer (x 1000):
More quantitative data for a demonstration project (El Paraíso, Copán, Tegucigalpa: 2018/HPV)

Check also the following factsheets: Honduras, Breast, Colorectal